Similar articles for PMID: 11809985

Year	Number of Results
1994	2
1995	8
1996	13
1997	13
1998	18
1999	24
2000	24
2001	32
2002	43
2003	16
2004	14
2005	21
2006	15
2007	20
2008	13
2009	7
2010	15
2011	10
2012	10
2013	8
2014	4
2015	3
2016	6
2017	8
2018	2
2019	3
2020	2
2021	1
2022	3
2023	2
2024	0

1

Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.

Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N. Clegg A, et al. Thorax. 2002 Jan;57(1):20-8. doi: 10.1136/thorax.57.1.20. Thorax. 2002. PMID: 11809985 Free PMC article. Review.

2

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.

Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. Clegg A, et al. Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068 Free article. Review.

3

Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?

Ferrigno D, Buccheri G. Ferrigno D, et al. Lung Cancer. 2000 Aug;29(2):91-104. doi: 10.1016/s0169-5002(00)00112-4. Lung Cancer. 2000. PMID: 10963840 Review.

4

The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).

Waters JS, O'Brien ME. Waters JS, et al. Br J Cancer. 2002 Aug 27;87(5):481-90. doi: 10.1038/sj.bjc.6600491. Br J Cancer. 2002. PMID: 12189541 Free PMC article. Review.

5

Rationale for non-platinum chemotherapy in advanced NSCLC.

Murren JR. Murren JR. Oncology (Williston Park). 2001 Jul;15(7 Suppl 8):29-34. Oncology (Williston Park). 2001. PMID: 11497229 Free article. Review.

6

Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.

Gridelli C, Hainsworth J. Gridelli C, et al. Lung Cancer. 2002 Dec;38 Suppl 4:37-41. doi: 10.1016/s0169-5002(02)00170-8. Lung Cancer. 2002. PMID: 12480193 Review.

7

New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.

Bunn PA Jr, Kelly K. Bunn PA Jr, et al. Clin Cancer Res. 1998 May;4(5):1087-100. Clin Cancer Res. 1998. PMID: 9607565 Review.

8

[Gemcitabine].

Takeda K. Takeda K. Nihon Rinsho. 2002 May;60 Suppl 5:359-65. Nihon Rinsho. 2002. PMID: 12101689 Review. Japanese. No abstract available.

9

Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.

Plosker GL, Hurst M. Plosker GL, et al. Pharmacoeconomics. 2001;19(11):1111-34. doi: 10.2165/00019053-200119110-00005. Pharmacoeconomics. 2001. PMID: 11735678 Review.

10

Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.

Lynch TJ Jr. Lynch TJ Jr. Semin Oncol. 2001 Jun;28(3 Suppl 9):5-9. doi: 10.1053/sonc.2001.24601. Semin Oncol. 2001. PMID: 11444253 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

345 results

Results by year